BOX/SEO

PTO/SB/05 (08-00)

Please type a plus sign (+) inside this box — +

Approved for use through 10/31/2002 OMB 0551-0032 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. YU 132

First Inventor Peter M. Glazer

METHODS OF TARGETED MUTAGENESIS USING TRIPLE-HELIX FORMING OLIGONUCLEOTIDES

EL 717 749 145 US Express Mail Label No. (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission X See 37 CFR 1.27. (if applicable, all necessary) Specification [Total Pages 46] 3. X a. X Computer Readable Form (CRF) arrangement set forth below - Descriptive title of the invention b. Specification Sequence Listing on: - Cross Reference to Related Applications i. ☐ CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, ii. 🗷 paper or a computer program listing appendix c. | X | Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) 9. - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure 10. (when there is an assignee) Attorney English Translation Document (if applicable) 11. 4. X Drawing(s) (35 U.S.C. 113) [Total Sheets 2] Copies of IDS Information Disclosure 5. Oath or Declaration [Total Pages 2] 12. Citations Statement (IDS)/PTO-1449 unexecuted Preliminary Amendment 13 a. Copy from a prior application (37 CFR 1.63 (d)) Return Receipt Postcard (MPEP 503) (for continuation/divisional with Box 17 completed) 14. X (Should be specifically itemized) DELETION OF INVENTOR(S) Certified Copy of Priority Document(s) (if foreign priority is claimed) 15 Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR Check for \$370 00 16. X Other: 1 63(d)(2) and 1 33(b) 6. X Application Data Sheet. See 37 CFR 1.76 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: of prior application No X Continuation-in-part (CIP) Continuation Divisional Examiner Myers, C. Group / Art Unit __1655 Pnor application information For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 18, CORRESPONDENCE ADDRESS Customer Number or Bar Code Label X Correspondence address below Patrea L. Pabst Name Holland & Knight LLP 2000 One Atlantic Center 1201 West Peachtree Street Address Atlanta GA 30309-3400 City State Zip Code 404-817-8588 404-817-8473 USA Telephone Fax Country Rivka D. Monheit 48,731 Name (Print/Type) Registration No. (Attorney/Agent) Kirba D. Monheit 10/15/01 Signature Date

Burden Hour Statement This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

10/15/01

Date

Under the Paperwork Reduction Act of 1995, no persons are required to

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision

TOTAL AMOUNT OF PAYMENT

(\$)	370	.00

Complete if Known		
Application Number		
Filing Date	October 15, 2001	
First Named Inventor	Peter M. Glazer	
Examiner Name		
Group Art Unit		
Attorney Docket No.	YU 132	

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued)			
1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to	3. ADDITIONAL FEES Large Entity Small Entity			
Deposit Account 50-1868	Fee Fee Fee Fee Fee Description Fee Pe Code (\$) Code (\$)			
Number	105 130 205 65 Surcharge - late filing fee or oath			
Deposit Account Name Holland & Knight LLP	127 50 227 25 Surcharge - late provisional filing fee or cover sheet			
Charge Any Additional Fee Required Under 37 CFR 1 16 and 1 17	139 130 139 130 Non-English specification			
— Glidel 37 Of R 7 10 dild 7 17	147 2,520 147 2,520 For filing a request for ex parte reexamination			
See 37 CFR 1 27	112 920* 112 920* Requesting publication of SIR prior to Examiner action			
2. X Payment Enclosed: X Check Credit card Order Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
	115 110 215 55 Extension for reply within first month			
FEE CALCULATION	116 390 216 195 Extension for reply within second month			
1. BASIC FILING FEE	117 890 217 445 Extension for reply within third month			
Large Entity Small Entity Fee Fee Fee Fee Description	118 1,390 218 695 Extension for reply within fourth month			
Code (\$) Code (\$)	128 1,890 228 945 Extension for reply within fifth month			
101 710 201 355 Utility filing fee 370.00	119 310 219 155 Notice of Appeal			
106 320 206 160 Design filing fee	120 310 220 155 Filing a brief in support of an appeal			
107 490 207 245 Plant filing fee	121 270 221 135 Request for oral hearing			
108 710 208 355 Reissue filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding			
114 150 214 75 Provisional filing fee	140 110 240 55 Petition to revive - unavoidable			
SUBTOTAL (1) (\$) 370.00	141 1,240 241 620 Petition to revive - unintentional			
2. EXTRA CLAIM FEES	142 1,240 242 620 Utility issue fee (or reissue)			
Fee from	143 440 243 220 Design issue fee			
Extra Claims below Fee Paid Total Claims $25 - 20 = 5 \times 9.00 = 45.00$	144 600 244 300 Plant issue fee			
Independent 3 3 = 0 x =	122 130 122 130 Petitions to the Commissioner			
Claims Multiple Dependent	123 50 123 50 Petitions related to provisional applications			
	126 240 126 240 Submission of Information Disclosure Stmt			
Large Entity Small Entity Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20	146 710 246 355 Filing a submission after final rejection (37 CFR § 1 129(a))			
102 80 202 40 Independent claims in excess of 3	149 710 249 355 For each additional invention to be			
104 270 204 135 Multiple dependent claim, if not paid 109 80 209 40 ** Reissue independent claims	examined (37 CFR § 1 129(b)) 179 279 355 Request for Continued Examination (RCE)			
109 80 209 40 ** Reissue independent claims over original patent				
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	of a design application			
Other fee (specify)				
SUBTOTAL (2) (\$) 45.00	Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)			
SUBMITTED BY Complete (if applicable)				
Name (PrintiType) Rivka D. Monheit	Registration No (404) 817-8514			
Mano (mino type) NIVNA D. WIUTITEIL	(AttorneylAgent) 40,101 (101) 011 0011			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Monkeit

Burden Hour Statement This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231.

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Peter M. Glazer

Serial No.:

Express Mail Label

No.: EL 717 749 145 US

Filed:

October 15, 2001

Date of Deposit:

October 15, 2001

For:

TRIPLE-HELIX FORMING OLIGONUCLEOTIDES FOR TARGETED

MUTAGENESIS

Box Patent Application Commissioner of Patents and Trademarks Washington, D.C. 2023l

EXPRESS MAIL TRANSMITTAL LETTER FOR PATENT APPLICATION AND CERTIFICATE OF MAILING

Sir:

Pursuant to 35 U.S.C. § 21(a) as amended by Public Law 97-247 and 37 C.F.R. § 1.10, applicant encloses for filing the attached patent application entitled "Triple-Helix Forming Oligonucleotides for Targeted Mutagenesis". This application is a continuation-in-part of pending prior application U.S. Serial No. 09/411,291 filed October 4, 1999, entitled "Methods of Targeted Mutagenesis Using Triple-Helix Forming Oligonucleotides" (As Amended), by Peter M. Glazer, which is a divisional of U.S. Serial No. 08/476,712, filed June 7, 1995, entitled "Triple-Helix Forming Oligonucleotides for Targeted Mutagenesis", by Peter M. Glazer. The application includes 1 page of abstract, 41 pages of specification, 4 pages of claims, 4 pages of Sequence Listing, 2 sheets of formal drawings, and an unexecuted Declaration for Patent Application. An executed Declaration for Patent Application, Assignment of rights in the application from Peter M. Glazer to Yale University, Power of Attorney or Authorization of Agent, and a Statement Under 37 C.F.R. § 3.73(b) will be submitted shortly.

Title: "Triple-Helix Forming Oligonucleotides for Targeted Mutagenesis" Filed: October 15, 2001 Express Mail Transmittal Letter for Patent Application and Certificate of Mailing Express Mail Label No.: EL 717 749 145 US Date of Deposit: October 15, 2001

This application contains nucleic acid and/or protein sequences as defined in 37 C.F.R. §§ 1.821-1.825. Pursuant to 37 C.F.R. §§ 1.821-1.825, applicant encloses a 3½" diskette containing a computer-readable form of the Sequence Listing for the above-identified application. A paper copy of the Sequence Listing is incorporated into the application.

I declare that the material on the diskette is identical to the paper copy of the Sequence Listing present in the above-identified application, and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements may jeopardize the validity of the application or any patent issuing thereon.

A check in the amount of \$370.00 to cover the basic filing fee for a small entity is enclosed. The Commissioner is hereby authorized to charge Deposit Order Account No. 50-1868 in the amount of \$45.00 for the fee for 5 claims in excess of 20 claims. It is believed that this is the proper filing fee for a small entity as the application contains 3 independent claims, and a total of 25 claims.

This application is entitled to claim small entity status under 37 C.F.R. § 1.27.

This application is being filed on October 15, 2001 by mailing the application to Box Patent Application, Commissioner of Patents and Trademarks, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10. The Express Mail label number appears in the heading of this paper that is attached to the application papers pursuant to 37 C.F.R. § 1.10(b).

Title: "Triple-Helix Forming Oligonucleotides for Targeted Mutagenesis"
Filed: October 15, 2001
Express Mail Transmittal Letter for
Patent Application and Certificate of Mailing
Express Mail Label No.: EL 717 749 145 US
Date of Deposit: October 15, 2001

The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment in connection with this application, to Deposit Order Account No. 50-1868. To facilitate this process, applicant has enclosed a duplicate of this letter.

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq. HOLLAND & KNIGHT LLP Suite 2000, One Atlantic Center 1201 West Peachtree Street, N.E. Atlanta, Georgia 30309-3400

Respectfully submitted,

Rivka D. Monheit

Reg. No. 48,731

Date: October 15, 2001

HOLLAND & KNIGHT LLP Suite 2000, One Atlantic Center 1201 West Peachtree Street, N.E. Atlanta, Georgia 30309-3400 (404) 817-8514 (Telephone) (404) 817-8588 (Fax) Title: "Triple-Helix Forming Oligonucleotides for Targeted Mutagenesis" Filed: October 15, 2001 Express Mail Transmittal Letter for Patent Application and Certificate of Mailing Express Mail Label No.: EL 717 749 145 US Date of Deposit: October 15, 2001

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this Express Mail Transmittal Letter for Patent Application and any documents referred to as attached therein are being deposited with the United States Postal Service on this date, October 15, 2001, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, Express Mail Label No. EL 717 749 145 US, addressed to Box Patent Application, Commissioner of Patents and Trademarks, Washington, D.C. 20231.

ear Sichs

Date: October 15, 2001

ATL1 #487849 v1